Anfarm Hellas S.A. - Main Component
Active Substance | Strength | Form |
---|---|---|
Palonosetron | 250mcg/5ml | Inj.Sol |
Pantoprazole | 40mg/Vial | Pd.Inj.Sol |
PosaconazoleUnder Development | 40 mg/mL | Oral Suspension |
PosaconazoleUnder Development | 100mg/tab | G.R. tabs |
PosaconazoleUnder Development | 300 mg | C.So.In |
Active Substance | Strength | Form |
---|---|---|
Palonosetron | 250mcg/5ml | Inj.Sol |
Pantoprazole | 40mg/Vial | Pd.Inj.Sol |
PosaconazoleUnder Development | 40 mg/mL | Oral Suspension |
PosaconazoleUnder Development | 100mg/tab | G.R. tabs |
PosaconazoleUnder Development | 300 mg | C.So.In |
Active Substance | Strength | Form | Market Availability |
---|---|---|---|
Palonosetron | 250mcg/5ml | Inj.Sol | International |
Pantoprazole | 40mg/Vial | Pd.Inj.Sol | International |
PosaconazoleUnder Development | 40 mg/mL | Oral Suspension | TBC |
PosaconazoleUnder Development | 100mg/tab | G.R. tabs | TBC |
PosaconazoleUnder Development | 300 mg | C.So.In | Q1 / Q2 2025 |